Summit Therapeutics Inc. (SMMT) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 384.04M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | (m) | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $384.04M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $794.12M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $732.42M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $631.66M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $520.27M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $52.57M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $0.00 | $50.98M | $-226.00M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $0.00 | $48.72M | $-196.59M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $30.05M | $-158.71M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $80.46M | (m) | $20.84M | $-114.89M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $59.47M | $0.00 | $14.11M | $-609.65M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $40.04M | $0.00 | $8.01M | $-593.74M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $41.77M | $220.00K | $10.11M | $-590.19M | (m) | 18985.91% | 4593.64% | (m) | (m) |
| 2023-03-31 | $41.33M | $455.00K | $10.73M | $-587.09M | $12.58M | 9082.64% | 2357.58% | -46.68× | Reported |
| 2022-12-31 | $52.00M | $705.00K | $11.95M | $-72.09M | $4.40M | 7375.74% | 1694.75% | -16.38× | Reported |
| 2022-09-30 | $69.72M | $956.00K | $14.91M | $-77.84M | $1.53M | 7292.89% | 1559.62% | -50.74× | Reported |
| 2022-06-30 | $72.61M | $2.04M | $14.76M | $-80.38M | $844.00K | 3550.81% | 721.56% | -95.24× | Reported |
| 2022-03-31 | $87.53M | $1.87M | $15.93M | $-91.42M | (m) | 4688.22% | 853.35% | (m) | (m) |
| 2021-12-31 | $85.35M | $1.81M | $12.80M | $-86.19M | $281.00K | 4718.19% | 707.79% | -306.71× | Reported |
| 2021-09-30 | $75.31M | $1.74M | $7.76M | $-71.69M | (m) | 4320.65% | 445.32% | (m) | (m) |
| 2021-06-30 | $69.09M | $615.00K | $5.48M | $-69.15M | (m) | 11234.47% | 890.89% | (m) | (m) |
| 2021-03-31 | $58.74M | $728.00K | $2.34M | $-60.78M | (m) | 8068.82% | 321.02% | (m) | (m) |
| 2020-12-31 | $53.27M | $860.00K | $1.77M | $-53.19M | $255.00K | 6194.65% | 205.35% | -208.60× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-01-31 | $52.00M | $57.09M | $6.29M | $6.00M | $615.00K | 91.09% | 11.03% | 9.76× | Reported |
| 2018-01-31 | $37.72M | $16.10M | $2.09M | $-28.37M | $1.54M | 234.24% | 12.98% | -18.37× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |